Baliopharm AG is a biotechnology company focusing on the development of novel antibody-based therapeutics for the treatment of autoimmune diseases like rheumatoid arthritis, Crohn`s disease, psoriasis and multiple sclerosis, and for cancer. Baliopharm's antibody pipeline consisting of two selective TNF-R1 antagonists, Atrosab and Atrosimab and the bispecific anti-CD20/CD95 antibody construct, Novotarg. Baliopharm was founded in 2011 as a spin-off of Celonic AG, an internationally operating service provider in the area of contract development and manufacturing of biopharmaceuticals operating since 1998. Baliopharm AG is located in Basel (Switzerland).
View Top Employees from Baliopharm AG| Website | http://www.baliopharm.com |
| Revenue | $7 million |
| Employees | View employees |
| Founded | 2011 |
| Address | Staenzlergasse 4, Basel, Basel-City 4051, CH |
| Phone | +41 61 205 39 10 |
| Industry | Biotechnology, Pharmaceuticals, Science and Engineering, Healthcare, Therapeutics, Health Care |
| Competitors | Apitope, CuraVac Europe, Kanyos Bio, Kineta Inc, Protalex, Inc. |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 541713 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 54171 Companies |
Looking for a particular Baliopharm AG employee's phone or email?
Baliopharm AG Questions
The Baliopharm AG annual revenue was $7 million in 2023.
Baliopharm AG is based in Basel, Basel-City.
The NAICS codes for Baliopharm AG are [541713, 541, 5417, 54, 54171].
The SIC codes for Baliopharm AG are [873, 87].
